Molecular oncology: what is needed to speed access to innovative therapies in clinical research?

Auteurs : Gourari K, Awada A, Kotecki N
Année : 2022
Journal : Curr Opin Oncol
Volume : 34
Pages : 575-578

First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors.

Auteurs : Kim TW, Burris HA, de Miguel Luken MJ, Pishvaian MJ, Bang YJ, Gordon M, Awada A, Camidge DR, Hodi FS, McArthur GA, Miller WH, Cervantes A, Chow LQ, Lesokhin AM, Rutten A, Sznol M, Rishipathak D, Chen SC, Stefanich E, Pourmohamad T, Anderson M, Kim J, Huseni M, Rhee I, Siu LL
Année : 2022
Journal : Clin Cancer Res
Volume : 28
Pages : 3452-3463

Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancer.

Auteurs : Schettini F, Venturini S, Giuliano M, Lambertini M, Pinato DJ, Onesti CE, De Placido P, Harbeck N, Lüftner D, Denys H, Van Dam P, Arpino G, Zaman K, Mustacchi G, Gligorov J, Awada A, Campone M, Wildiers H, Gennari A, Tjan-Heijnen V, Bartsch R, Cortes J, Paris I, Martín M, De Placido S, Del Mastro L, Jerusalem G, Curigliano G, Prat A, Generali D
Année : 2022
Journal : Cancer Treat Rev
Volume : 111
Pages : 102468

Cytokine Landscape in Central Nervous System Metastases.

Auteurs : Marin J, Journe F, Ghanem GE, Awada A, Kindt N
Année : 2022
Journal : Biomedicines
Volume : 10

First-in-human phase 1 dose-escalation study of CAN04, a first-in-class interleukin-1 receptor accessory protein (IL1RAP) antibody in patients with solid tumours.

Auteurs : Robbrecht D, Jungels C, Sorensen MM, Spanggaard I, Eskens F, Fretland SØ, Guren TK, Aftimos P, Liberg D, Svedman C, Thorsson L, Steeghs N, Awada A
Année : 2022
Journal : Br J Cancer
Volume : 126
Pages : 1010-1017

Beta-2 Adrenergic Receptor Gene Expression in HER2-Positive Early-Stage Breast Cancer Patients: A Post-hoc Analysis of the NCCTG-N9831 (Alliance) Trial.

Auteurs : Caparica R, Ma Y, de Angelis C, Richard F, Desmedt C, Awada A, Piccart M, Perez EA, Moreno-Aspitia A, Badve S, Thompson EA, de Azambuja E
Année : 2022
Journal : Clin Breast Cancer
Volume : 22
Pages : 308-318

FUS::CREM-rearranged malignant epithelioid neoplasm mimicking neuroendocrine neoplasm of unknown primary.

Auteurs : Demetter P, Awada A, Aftimos P, Liberale G, Jungels C, Gomez-Galdon M, Saiselet M, de Saint Aubain N
Année : 2022
Journal : Histopathology
Volume : 80
Pages : 871-873

Molecular diagnosis and targeted treatment of advanced follicular cell-derived thyroid cancer in the precision medicine era.

Auteurs : Capdevila J, Awada A, Führer-Sakel D, Leboulleux S, Pauwels P
Année : 2022
Journal : Cancer Treat Rev
Volume : 106
Pages : 102380

Author Correction: FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer.

Auteurs : Gombos A, Venet D, Ameye L, Vuylsteke P, Neven P, Richard V, Duhoux FP, Laes JF, Rothe F, Sotiriou C, Paesmans M, Awada A, Guiot T, Flamen P, Piccart-Gebhart M, Ignatiadis M, Gebhart G
Année : 2022
Journal : NPJ Breast Cancer
Volume : 8
Pages : 38

Clinical Implications of Body Mass Index in Metastatic Breast Cancer Patients Treated With Abemaciclib and Endocrine Therapy.

Auteurs : Franzoi MA, Eiger D, Ameye L, Ponde N, Caparica R, de Angelis C, Brandão M, Desmedt C, Di Cosimo S, Kotecki N, Lambertini M, Awada A, Piccart-Gebhart M, Azambuja E
Année : 2021
Journal : J Natl Cancer Inst
Volume : 113
Pages : 462-470

Abemaciclib, a third CDK 4/6 inhibitor for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer.

Auteurs : El Hachem G, Gombos A, Awada A
Année : 2021
Journal : Expert Rev Anticancer Ther
Volume : 21
Pages : 81-92

Selective Oral MEK1/2 Inhibitor Pimasertib: A Phase I Trial in Patients with Advanced Solid Tumors.

Auteurs : Delord JP, Italiano A, Awada A, Aftimos P, Houédé N, Lebbé C, Pages C, Lesimple T, Dinulescu M, Schellens JHM, Leijen S, Rottey S, Kruse V, Kefford R, Faivre S, Gomez-Roca C, Scheuler A, Massimini G, Raymond E
Année : 2021
Journal : Target Oncol
Volume : 16
Pages : 37-46

Selective Oral MEK1/2 Inhibitor Pimasertib in Metastatic Melanoma: Antitumor Activity in a Phase I, Dose-Escalation Trial.

Auteurs : Lebbé C, Italiano A, Houédé N, Awada A, Aftimos P, Lesimple T, Dinulescu M, Schellens JHM, Leijen S, Rottey S, Kruse V, Kefford R, Raymond E, Faivre S, Pages C, Gomez-Roca C, Schueler A, Goodstal S, Massimini G, Delord JP
Année : 2021
Journal : Target Oncol
Volume : 16
Pages : 47-57

A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumours.

Auteurs : van Bussel MTJ, Awada A, de Jonge MJA, Mau-Sørensen M, Nielsen D, Schöffski P, Verheul HMW, Sarholz B, Berghoff K, El Bawab S, Kuipers M, Damstrup L, Diaz-Padilla I, Schellens JHM
Année : 2021
Journal : Br J Cancer
Volume : 124
Pages : 728-735

Tyrosine-Dependent Phenotype Switching Occurs Early in Many Primary Melanoma Cultures Limiting Their Translational Value.

Auteurs : Najem A, Wouters J, Krayem M, Rambow F, Sabbah M, Sales F, Awada A, Aerts S, Journe F, Marine JC, Ghanem GE
Année : 2021
Journal : Front Oncol
Volume : 11
Pages : 780654

Humanized Mice as a Valuable Pre-Clinical Model for Cancer Immunotherapy Research.

Auteurs : Cogels MM, Rouas R, Ghanem GE, Martinive P, Awada A, Van Gestel D, Krayem M
Année : 2021
Journal : Front Oncol
Volume : 11
Pages : 784947

Current landscape of ESMO/ASCO Global Curriculum adoption and medical oncology recognition: a global survey.

Auteurs : Cufer T, Kosty M, Osterlund P, Jezdic S, Pyle D, Awada A, Close J, El-Saghir N, Lordick F, Rutkowski P, Tfayli A, Wildiers H
Année : 2021
Journal : ESMO Open
Volume : 6
Pages : 100219

Avelumab as neoadjuvant therapy in patients with urothelial non-metastatic muscle invasive bladder cancer: a multicenter, randomized, non-comparative, phase II study (Oncodistinct 004 - AURA trial).

Auteurs : Martinez Chanza N, Soukane L, Barthelemy P, Carnot A, Gil T, Casert V, Vanhaudenarde V, Sautois B, Staudacher L, Van Den Brande J, Culine S, Seront E, Gizzi M, Albisinni S, Tricard T, Fantoni JC, Paesmans M, Caparica R, Roumeguere T, Awada A
Année : 2021
Journal : BMC Cancer
Volume : 21
Pages : 1292

The NHance^® Mutation-Equipped Anti-MET Antibody ARGX-111 Displays Increased Tissue Penetration and Anti-Tumor Activity in Advanced Cancer Patients.

Auteurs : Aftimos P, Rolfo C, Rottey S, Barthélémy P, Borg C, Park K, Oh DY, Kim SW, De Jonge N, Hanssens V, Zwanenpoel K, Molthoff C, Vugts D, Dreier T, Verheesen P, van Dongen GAMS, Jacobs J, Van Rompaey L, Hultberg A, Michieli P, Pauwels P, Fung S, Thibault A, de Haard H, Leupin N, Awada A
Année : 2021
Journal : Biomedicines
Volume : 9

Safety, Antitumor Activity, and T-cell Responses in a Dose-Ranging Phase I Trial of the Oncolytic Peptide LTX-315 in Patients with Solid Tumors.

Auteurs : Spicer J, Marabelle A, Baurain JF, Jebsen NL, Jøssang DE, Awada A, Kristeleit R, Loirat D, Lazaridis G, Jungels C, Brunsvig P, Nicolaisen B, Saunders A, Patel H, Galon J, Hermitte F, Camilio KA, Mauseth B, Sundvold V, Sveinbjørnsson B, Rekdal Ø
Année : 2021
Journal : Clin Cancer Res
Volume : 27
Pages : 2755-2763